DE69928411D1 - Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung - Google Patents

Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung

Info

Publication number
DE69928411D1
DE69928411D1 DE69928411T DE69928411T DE69928411D1 DE 69928411 D1 DE69928411 D1 DE 69928411D1 DE 69928411 T DE69928411 T DE 69928411T DE 69928411 T DE69928411 T DE 69928411T DE 69928411 D1 DE69928411 D1 DE 69928411D1
Authority
DE
Germany
Prior art keywords
protein
comparable
kinase activity
kid
vitro kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69928411T
Other languages
English (en)
Inventor
A Mctigue
Chris Pinko
V Parast
R Gehring
Chen-Chen Kan
Krzysztof Appelt
A Wickersham
Edward Showalter
Anna-Maria Tempcyzk-Russell
Barbara Mroczkowski
Ernesto Villafranca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Original Assignee
Agouron Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC filed Critical Agouron Pharmaceuticals LLC
Application granted granted Critical
Publication of DE69928411D1 publication Critical patent/DE69928411D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C30—CRYSTAL GROWTH
    • C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
    • C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Materials Engineering (AREA)
  • Metallurgy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69928411T 1998-09-08 1999-09-07 Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung Expired - Lifetime DE69928411D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9950398P 1998-09-08 1998-09-08
PCT/US1999/020319 WO2000014105A1 (en) 1998-09-08 1999-09-07 Modifications of the vegf receptor-2 protein and methods of use

Publications (1)

Publication Number Publication Date
DE69928411D1 true DE69928411D1 (de) 2005-12-22

Family

ID=22275320

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69928411T Expired - Lifetime DE69928411D1 (de) 1998-09-08 1999-09-07 Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung

Country Status (10)

Country Link
US (5) US6316603B1 (de)
EP (1) EP1109823B1 (de)
JP (1) JP2002534058A (de)
KR (1) KR100442221B1 (de)
AT (1) ATE310018T1 (de)
AU (1) AU760008B2 (de)
CA (1) CA2340598A1 (de)
DE (1) DE69928411D1 (de)
ES (1) ES2252972T3 (de)
WO (1) WO2000014105A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000014105A1 (en) * 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
EP1280901B1 (de) * 2000-03-29 2005-01-26 Max-Planck-Gesellschaft Raumform von tpr-strukturmotiv enthaltenden polypeptiden mit chaperon-bindungsfunktion, deren kristalle und verbindungen zur inhibierung derartiger polypeptide
JP2004508016A (ja) * 2000-06-07 2004-03-18 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド Ｖｅｇｆキナーゼドメインのモジュレーターを検出する方法
ES2238463T3 (es) * 2000-08-18 2005-09-01 Agouron Pharmaceuticals, Inc. Hidroxiimino-fluorenos heterociclicos y uso para inhibir proteina-quinasas.
WO2002059110A1 (en) 2000-12-21 2002-08-01 Glaxo Group Limited Pyrimidineamines as angiogenesis modulators
WO2003064406A1 (en) * 2002-01-07 2003-08-07 Sequoia Pharmaceuticals Resistance-repellent retroviral protease inhibitors
US20040229293A1 (en) * 2002-05-21 2004-11-18 Po-Ying Chan-Hui Surface receptor complexes as biomarkers
BRPI0408961A (pt) * 2003-04-01 2006-10-31 Monogram Biosciences Inc método para determinar uma situação de doença de um paciente, método para selecionar um paciente para tratamento de um cáncer com um ou mais medicamentos de ação dimérica de erbb, e, método para determinar uma situação cancerosa de um paciente
WO2004092217A1 (en) * 2003-04-17 2004-10-28 Pfizer Inc. Crystal structure of vegfrkd: ligand complexes and methods of use thereof
US20060030016A1 (en) * 2003-12-05 2006-02-09 Graham Cheetham Crystal structure of interleukin-2 tyrosine kinase (ITK) and binding pockets thereof
US20060094081A1 (en) * 2004-10-22 2006-05-04 Carsten Schubert Crystal structure of the c-fms kinase domain: applications and use of heterologous substitutions of kinase insert domains for crystallization
JO3067B1 (ar) * 2008-10-27 2017-03-15 Glaxosmithkline Llc بيرميدينات بيرازولو امينو كمثبطات ل fak
WO2023164224A1 (en) * 2022-02-28 2023-08-31 The Board Of Trustees Of The Leland Stanford Junior University Functionalized nanoclusters and their use in treating bacterial infections

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966849A (en) 1985-09-20 1990-10-30 President And Fellows Of Harvard College CDNA and genes for human angiogenin (angiogenesis factor) and methods of expression
US5217999A (en) 1987-12-24 1993-06-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US6372438B1 (en) * 1988-02-02 2002-04-16 The Regents Of The University Of California Human platelet-derived growth factor receptors
US5326905A (en) 1990-04-02 1994-07-05 Pfizer Inc. Benzylphosphonic acid tyrosine kinase inhibitors
US5302606A (en) 1990-04-16 1994-04-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Styryl-substituted pyridyl compounds which inhibit EGF receptor tyrosine kinase
US5409930A (en) 1991-05-10 1995-04-25 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US6194439B1 (en) 1991-05-29 2001-02-27 Pfizer Inc. Tricyclic polyhydroxylic tyrosine kinase inhibitors
RU2155187C2 (ru) 1992-08-06 2000-08-27 Варнер-Ламберт Компани Производные индола, их таутомеры, смеси их изомеров или отдельные изомеры и фармацевтически приемлемые соли, фармацевтическая композиция с антиопухолевой или ингибирующей протеин-тирозинкиназу активностью и способ торможения зависящего от протеин-тирозинкиназы заболевания или борьбы с аберрантным ростом клеток млекопитающего или человека.
US5330992A (en) 1992-10-23 1994-07-19 Sterling Winthrop Inc. 1-cyclopropyl-4-pyridyl-quinolinones
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
CA2287538A1 (en) 1997-04-25 1998-11-05 Collateral Therapeutics Truncated vegf-related proteins
WO2000014105A1 (en) * 1998-09-08 2000-03-16 Agouron Pharmaceuticals, Inc. Modifications of the vegf receptor-2 protein and methods of use
US7432347B2 (en) * 2000-10-30 2008-10-07 Protein Crystal Co., Ltd Cytoplasmic polyhedrosis virus polyhedrin protein complex

Also Published As

Publication number Publication date
US20020051965A1 (en) 2002-05-02
AU5809399A (en) 2000-03-27
US20020164641A1 (en) 2002-11-07
US6316603B1 (en) 2001-11-13
WO2000014105A1 (en) 2000-03-16
ATE310018T1 (de) 2005-12-15
KR100442221B1 (ko) 2004-07-30
CA2340598A1 (en) 2000-03-16
US20020127538A1 (en) 2002-09-12
EP1109823A4 (de) 2003-06-18
ES2252972T3 (es) 2006-05-16
AU760008B2 (en) 2003-05-08
EP1109823A1 (de) 2001-06-27
KR20010086386A (ko) 2001-09-10
EP1109823B1 (de) 2005-11-16
US6849721B2 (en) 2005-02-01
JP2002534058A (ja) 2002-10-15
US6794146B2 (en) 2004-09-21
US6753416B2 (en) 2004-06-22
US6784285B1 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
Nybakken et al. Hedgehog signal transduction: recent findings
DE69928411D1 (de) Modifikationen des vegf-rezeptor-2 proteins und verfahren zu seiner verwendung
Butler et al. Poly (ADP-ribose) polymerase binds with transcription enhancer factor 1 to MCAT1 elements to regulate muscle-specific transcription
Park et al. HuD RNA recognition motifs play distinct roles in the formation of a stable complex with AU-rich RNA
Sukhodolets et al. The 32-kilodalton subunit of replication protein A interacts with menin, the product of the MEN1 tumor suppressor gene
Dudenhöffer et al. Specific mismatch recognition in heteroduplex intermediates by p53 suggests a role in fidelity control of homologous recombination
Shigemoto et al. Identification and characterisation of a developmentally regulated mammalian gene that utilises–1 programmed ribosomal frameshifting
Ashe et al. Dpp signaling thresholds in the dorsal ectoderm of the Drosophila embryo
Nowak et al. The transcription factor Yin Yang 1 is an activator of BACE1 expression
Li et al. Myocyte enhancer factor 2A and 2D undergo phosphorylation and caspase-mediated degradation during apoptosis of rat cerebellar granule neurons
Sigvardsson Overlapping expression of early B-cell factor and basic helix-loop-helix proteins as a mechanism to dictate B-lineage-specific activity of the λ 5 promoter
Rooke et al. Roles for SR proteins and hnRNP A1 in the regulation of c-src exon N1
Benson et al. Identification of a homeodomain binding element in the bone sialoprotein gene promoter that is required for its osteoblast-selective expression
Rovner et al. Chimeric substitutions of the actin-binding loop activate dephosphorylated but not phosphorylated smooth muscle heavy meromyosin
Zhang et al. Regulation of the activity of IFN-γ promoter elements during Th cell differentiation
Karadsheh et al. Neuronal restrictive silencing element is found in the KCC2 gene: molecular basis for KCC2-specific expression in neurons
DE69333776D1 (de) Dna codierend für den menschlichen 5-ht 1f rezeptor und ihre verwendung
Zhou et al. Genomic structure and expression of the murine Hmgi-c gene
Huang et al. Redox Modulation of AP-2 DNA Binding Activityin Vitro
US20100311811A1 (en) Rna-mediated epigenetic regulation of gene transcription
Capovilla et al. Functional dominance among Hox genes: repression dominates activation in the regulation of Dpp
Vincentz et al. Exclusion of Dlx5/6 expression from the distal-most mandibular arches enables BMP-mediated specification of the distal cap
Simpson et al. Differential expression and subcellular distribution of the mouse metastasis-associated proteins Mta1 and Mta3
Elrick et al. A short sequence within two purine-rich enhancers determines 5′ splice site specificity
Dang et al. A region between− 141 and− 61 bp containing a proximal AP‐1 is essential for constitutive expression of urokinase‐type plasminogen activator receptor

Legal Events

Date Code Title Description
8332 No legal effect for de